AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of EUR 198.58 billion. The enterprise value is 222.86 billion.
Market Cap | 198.58B |
Enterprise Value | 222.86B |
Important Dates
The next estimated earnings date is Tuesday, July 29, 2025.
Earnings Date | Jul 29, 2025 |
Ex-Dividend Date | Feb 20, 2025 |
Share Statistics
Current Share Class | 1.55B |
Shares Outstanding | n/a |
Shares Change (YoY) | +0.08% |
Shares Change (QoQ) | -0.06% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 27.62 and the forward PE ratio is 15.68.
PE Ratio | 27.62 |
Forward PE | 15.68 |
PS Ratio | 3.90 |
PB Ratio | 5.22 |
P/TBV Ratio | n/a |
P/FCF Ratio | 19.25 |
P/OCF Ratio | 16.40 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.04, with an EV/FCF ratio of 21.60.
EV / Earnings | 30.99 |
EV / Sales | 4.41 |
EV / EBITDA | 13.04 |
EV / EBIT | 17.84 |
EV / FCF | 21.60 |
Financial Position
The company has a current ratio of 0.90, with a Debt / Equity ratio of 0.77.
Current Ratio | 0.90 |
Quick Ratio | 0.69 |
Debt / Equity | 0.77 |
Debt / EBITDA | 1.70 |
Debt / FCF | 2.84 |
Interest Coverage | 10.16 |
Financial Efficiency
Return on equity (ROE) is 19.79% and return on invested capital (ROIC) is 11.73%.
Return on Equity (ROE) | 19.79% |
Return on Assets (ROA) | 8.16% |
Return on Invested Capital (ROIC) | 11.73% |
Return on Capital Employed (ROCE) | 17.65% |
Revenue Per Employee | 539,442 |
Profits Per Employee | 76,253 |
Employee Count | 94,300 |
Asset Turnover | 0.53 |
Inventory Turnover | 1.72 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.37% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -13.37% |
50-Day Moving Average | 124.58 |
200-Day Moving Average | 133.75 |
Relative Strength Index (RSI) | 58.05 |
Average Volume (20 Days) | 11,599 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of EUR 50.87 billion and earned 7.19 billion in profits. Earnings per share was 4.60.
Revenue | 50.87B |
Gross Profit | 41.94B |
Operating Income | 12.59B |
Pretax Income | 8.60B |
Net Income | 7.19B |
EBITDA | 16.91B |
EBIT | 12.59B |
Earnings Per Share (EPS) | 4.60 |
Balance Sheet
The company has 4.99 billion in cash and 29.34 billion in debt, giving a net cash position of -24.35 billion.
Cash & Cash Equivalents | 4.99B |
Total Debt | 29.34B |
Net Cash | -24.35B |
Net Cash Per Share | n/a |
Equity (Book Value) | 38.05B |
Book Value Per Share | 24.50 |
Working Capital | -2.77B |
Cash Flow
In the last 12 months, operating cash flow was 12.11 billion and capital expenditures -1.79 billion, giving a free cash flow of 10.32 billion.
Operating Cash Flow | 12.11B |
Capital Expenditures | -1.79B |
Free Cash Flow | 10.32B |
FCF Per Share | n/a |
Margins
Gross margin is 82.44%, with operating and profit margins of 24.75% and 14.14%.
Gross Margin | 82.44% |
Operating Margin | 24.75% |
Pretax Margin | 16.90% |
Profit Margin | 14.14% |
EBITDA Margin | 33.24% |
EBIT Margin | 24.75% |
FCF Margin | 20.28% |
Dividends & Yields
This stock pays an annual dividend of 2.93, which amounts to a dividend yield of 2.29%.
Dividend Per Share | 2.93 |
Dividend Yield | 2.29% |
Dividend Growth (YoY) | 10.55% |
Years of Dividend Growth | 3 |
Payout Ratio | 63.60% |
Buyback Yield | -0.08% |
Shareholder Yield | 2.21% |
Earnings Yield | 3.62% |
FCF Yield | 5.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | |
Lynch Upside | |
Graham Number | |
Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 3.08.
Altman Z-Score | 3.08 |
Piotroski F-Score | n/a |